Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.
Don’t miss the WestWind podcast with Dr. Jack West hosting Dr. Addeo to learn more about his path and challenges from Italy over UK to Switzerland.
He was trained and received his doctorate in Italy from the University School of Medicine in Turin. After his residency, he worked for another 4 years in Turin as a Consultant Oncologist. From 2010 to 2017 he further sharpened his interest in thoracic malignancies in the UK. First at the United Lincolnshire Hospital NHS Trust and later at the University Hospital Bristol, Dr. Addeo also took on the role as senior lecturer in Medical Oncology. As an active member of the NCRI Mesothelioma Working Group, he has also participated in several national and international NCRI drug studies. Dr. Addeo’s research continues to focus on drug development and translational aspects of precision medicine, immunotherapy and side effects, particularly in small and non-smal cell lung cancer (NSCLC) as well as melanoma.
During his time in the UK, Dr. Addeo developed further research interests in liquid biopsies, ctDNA analysis, and tumor mutation burden (TMB) in blood samples. For his research activities in this field he received a grant for a research proposal, which is still ongoing.
In September 2017, Dr. Addeo moved to Geneva, where he received the post of medical oncologist with a primary responsibility for Thoracic Malignancies.
Solange Peters, MD, PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at the University Hospital of Lausanne, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President-elect ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.
Professor Peters is currently in charge of teaching and patient care in the area of Thoracic Malignancies in the department of oncology of Lausanne University, where she is building a translational programme in collaboration with the molecular oncology laboratory directed by Dr. Hanahan at the Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute. Professor Peters’ main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also strongly involved and interested in multimodality trial building for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy.
Professor Peters’ current research projects are focused on multimodality stage III NSCLC treatment strategies, immunotherapy in limited small cell lung cancer and advanced thymic malignancies, advanced NSCLC, ALK inhibitors, HER2 inhibitors, as well as immunotherapy combinations and new immunomodulating treatments across thoracic malignancies. She acts as the local principal investigator (PI) for lung trials opened at Lausanne Cancer Centre, focused on phase I predictive biomarkers and thoracic malignancies immunotherapy, and is a co-PI of several other trials. Additionally, she acts as the scientific coordinator of the European Thoracic Oncology Platform (ETOP).
|8.30 – 9.00||Registration & Coffee|
|9.00||Welcome By Chairs||S. Peters &
|9.15||Latest Treatment Standards In First Line Non-Oncogene Addicted NSCLC||M. Pérol|
|9.45||Personalized Medicine With IO: Can We Tailor Immunotherapy Options To Patients?||J. Bauml|
|10.15||Integrating Immunotherapy Into Localized NSCLC||S. Patel|
|10.45||Open Discussion & Coffee Break|
|11.30||Small Cell Lung Cancer (SCLC): New Treatment Paradigms & A Glimpse Into The Development Of New Targets||S. Liu|
|12.00||The Art Of Balance: How To Manage Immune-Related Adverse Events Beyond Steroids||G. Banna|
|13.45||How To Chose Between TKIs & What Combinations Are Suitable For What Patient?||J. West|
|14.15||Actionable Mutations On the Horizon: Up & Coming Agents In Targeted Therapies||C. Rolfo|
|14.45||Debate: Oncogene-Addicted NSCLC Patients With Brain Mets Should Always Receive SRS||F. Caparrotti
& A. Calles
|15.30||Open Discussion & Coffee Break|
|16.15||Mesothelioma: New Therapeutic Strategies & Future Perspectives For A Difficult Disease With A Heavy Social Burden||A. Curioni|
|16.45||The Power Of Social Media In Oncology: What We Can Learn From Our Virtual Peers||G. Morgan|
|17.15||Final Questions and Wrap Up|
Hôpitaux Universitaires de Genève (HUG)
Rue Gabrielle-Perret-Gentil 4
1205 Geneva, Switzerland
International Lung Cancer SummitFollow
Leading MedOncs in Thoracic Cancer discuss recent discoveries & advances for the treatment of lung cancer at the ILCS. Register @ https://t.co/0ixI9mMVzl
Great work by @KartikSehgal_MD on outcomes with delays during immunotherapy. While somewhat different circumstances, these data are relevant in the #COVID19 era as we work to minimize exposures, minimize risk for our patients with lung cancer. #OncoAlert #LCSM #StayAtHome https://twitter.com/kartiksehgal_md/status/1245750805996744704
Delay/extension of pembro-based Rx for advanced NSCLC expected #COVID19. In preprint @medRxiv, our experience with outcomes in patients who received atleast ≥4 cycles and had delays/extensions. Results hypothesis-generating only but may be timely. Details & limitations👇#lcsm
We believe that medical education is now more important than ever: LIVE webcasts will be provided for the #LungSummit. More than 25 countries joined last year, "and we hope more this year."
Our chair @peters_solange invites you to join online on MAY 15! @UmbertoMalapel1 @Alfdoc2
Thanks @DavidCookeMD & @BrendonStilesMD.
A collaborative effort with @drdavidpalma @DoctorJSpicer @umanitoba @CancerCareMB @WesternU @mcgillu
Plan is for centers implementing this protocol locally & tracking outcomes. A strategy born of the unique needs of #covid19 era #LCSM https://twitter.com/davidcookemd/status/1245867951548272640
@biniamkidaneMD is affiliated with a canadian trial, looking for partners. #LCSM #TSSMN https://twitter.com/BrendonStilesMD/status/1245867634454749186
RCR @RCRadiologists has published guidance on "Reduced fractionation in lung cancer patients treated during COVID-19 pandemic". Comments are encouraged as likely to be updated as the situation changes. #radonc #lcsm #covid19 Please share https://www.rcr.ac.uk/sites/default/files/lung-cancer-radiotherapy-covid19.pdf